Latest Breaking News On - Emergency use list - Page 8 : comparemela.com

Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. This paves the way for Covaxin to get World Health Organisation s approval for its inclusion in the Emergency Use List of Covid-19 vaccines. The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. The safety analysis demonstrates that adverse events reported were similar to placebo, with 12 per cent of the subjects experiencing commonly known side effects and less than 0.5 per cent of them feeling serious adverse effects. The efficacy data further demonstrates 63.6 per cent protection against asympt

Krishna ellaBalram bhargavaNational institutes of healthIndian council of medical researchDepartment of health researchWorld health organisationBharat biotechEmergency use listNational institutesData safety monitoring boardManaging directorCovid vaccinesSecretary departmentHealth researchDirector general indian councilMedical research